Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
Confirmatory Results

In silico Repositioning of Approved Drugs Against Schistosoma mansoni Energy Metabolism Targets

Nicole Melo Calixto, Daniela Braz dos Santos, José Clecildo Barreto Bezerra, View ORCID ProfileLourival de Almeida Silva
doi: https://doi.org/10.1101/397059
Nicole Melo Calixto
1Department of Bioinformatics, Federal Institute of Education, Science and Technology Goiano -Campus Ceres, Ceres, Goiás, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Braz dos Santos
2LAERPH- Laboratory of Parasite-Host Relationship Study, Institute of Tropical Pathology and ublic Health of the Federal University of Goiás, Goiânia, Goiás, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Clecildo Barreto Bezerra
2LAERPH- Laboratory of Parasite-Host Relationship Study, Institute of Tropical Pathology and ublic Health of the Federal University of Goiás, Goiânia, Goiás, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lourival de Almeida Silva
1Department of Bioinformatics, Federal Institute of Education, Science and Technology Goiano -Campus Ceres, Ceres, Goiás, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lourival de Almeida Silva
  • For correspondence: lourival.silva@ifgoiano.edu.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Schistosomiasis is a neglected parasitosis caused by Schistosoma spp. Praziquantel is used for the chemoprophylaxis and treatment of this disease. Although this monotherapy is effective, the risk of resistance and its low efficiency against immature worms compromises its effectiveness. Therefore, it is necessary to develop new schistosomicide drugs. However, the development of new drugs is a long and expensive process. The repositioning of approved drugs has been proposed as a quick, cheap, and effective alternative to solve this problem. This study employs chemogenomic analysis with use of bioinformatics tools to search, identify, and analyze data on approved drugs with the potential to inhibit Schistosoma mansoni energy metabolism enzymes. The TDR Targets Database, Gene DB, Protein, DrugBank, Therapeutic Targets Database (TTD), Promiscuous, and PubMed databases were used. Fifty-nine target proteins were identified, of which 18 had one or more approved drugs. The results identified 20 potential drugs for schistosomiasis treatment, all approved for use in humans.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 21, 2018.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
In silico Repositioning of Approved Drugs Against Schistosoma mansoni Energy Metabolism Targets
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In silico Repositioning of Approved Drugs Against Schistosoma mansoni Energy Metabolism Targets
Nicole Melo Calixto, Daniela Braz dos Santos, José Clecildo Barreto Bezerra, Lourival de Almeida Silva
bioRxiv 397059; doi: https://doi.org/10.1101/397059
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
In silico Repositioning of Approved Drugs Against Schistosoma mansoni Energy Metabolism Targets
Nicole Melo Calixto, Daniela Braz dos Santos, José Clecildo Barreto Bezerra, Lourival de Almeida Silva
bioRxiv 397059; doi: https://doi.org/10.1101/397059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Bioinformatics
Subject Areas
All Articles
  • Animal Behavior and Cognition (4086)
  • Biochemistry (8759)
  • Bioengineering (6479)
  • Bioinformatics (23339)
  • Biophysics (11748)
  • Cancer Biology (9148)
  • Cell Biology (13245)
  • Clinical Trials (138)
  • Developmental Biology (7413)
  • Ecology (11368)
  • Epidemiology (2066)
  • Evolutionary Biology (15086)
  • Genetics (10397)
  • Genomics (14009)
  • Immunology (9118)
  • Microbiology (22039)
  • Molecular Biology (8778)
  • Neuroscience (47356)
  • Paleontology (350)
  • Pathology (1420)
  • Pharmacology and Toxicology (2480)
  • Physiology (3703)
  • Plant Biology (8049)
  • Scientific Communication and Education (1431)
  • Synthetic Biology (2208)
  • Systems Biology (6015)
  • Zoology (1249)